Market Overview

XOMA Says Sevier Initiated Proof-of-Concept Gevokizumab Study for Acute Coronary Syndrome Patients

Related XOMA
US Stock Futures Edge Lower Ahead Of Auto Sales
Morning Market Gainers
New finance chief at Xoma (Seeking Alpha)

XOMA Corporation (Nasdaq: XOMA) today announced its partner, Servier, has initiated the first Servier-sponsored proof-of-concept study in a cardiovascular indication. The study has opened for patient enrollment. The study is expected to enroll 45 patients who have experienced Acute Coronary Syndrome (ACS) in the past three to twelve months.  The objective of this study is to evaluate the effect of subcutaneous administration of 30 mg gevokizumab as compared to placebo in reducing arterial wall inflammation in patients with marked atherosclerotic plaque inflammation. The primary endpoint Servier will be assessing is the change in the mean target to background ratio (TBR) of the radioactive tracer FDG assessed by PET/CT after three months of treatment.  The study also will determine gevokizumab's effect on a number of cardiac and vascular biological blood biomarkers.

Posted-In: News


Related Articles (XOMA)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→